1063697-17-5Relevant articles and documents
Lysophosphatidic acid receptor antagonists and preparation method thereof
-
Paragraph 0479-0483, (2020/07/29)
The invention belongs to the technical field of medicinal chemistry, and particularly relates to lysophosphatidic acid receptor antagonists and a preparation method thereof. The applicant surprisinglyfinds that compounds provided by the invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospect, and can be used for preventing or treating diseases or symptoms related to LPAR1. The applicant also accidentally finds that the IC50 value of part of the compounds can be as low as 300 nM or below and even 50 nM or below.Moreover, the compounds disclosed by the invention have better safety, and the CC50 range of the compounds can reach 200 [mu]M or above. In addition, the compounds of the present invention have goodmetabolic stability in humans, rats, and mice, such excellent inhibitory activity being very desirable for their use as LPAR1 inhibitors in the above diseases or disorders. In addition, the preparation method of the compounds is simple, mild in reaction condition, high in product yield and suitable for industrial production.
TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE
-
Page/Page column 101, (2015/06/08)
The present invention relates to compounds of the formula (I), wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to thei
Design and synthesis of fluorinated iron chelators for metabolic study and brain uptake
Ma, Yongmin,Roy, Sourav,Kong, Xiaole,Chen, Yulin,Liu, Dingyong,Hider, Robert C.
supporting information; experimental part, p. 2185 - 2195 (2012/05/04)
A range of fluorinated 3-hydroxypyridin-4-ones has been synthesized where fluorine or fluorinated substituent was attached at 2- or 5- position of the pyridine ring in order to improve chemical and biological properties of 3-hydroxypyridin-4-ones. The synthetic route is different from conventional counterparts where a functional group is introduced to a preformed 3-hydroxypyridin-4-one ring. Herein, we introduce a novel method which starts with a fluorine containing precursor and the two hydroxyl groups at 3- and 4- positions of the pyridine ring are introduced at a later stage. The pK a values of the free ligands and the affinity constants of their iron complexes demonstrate that the presence of fluorine dramatically alters the values. The distribution coefficient values of the free ligands and corresponding iron(III) complexes between 1-octanol and MOPS buffer (pH 7.4) are also influenced. Glucuronidation and oxidation studies of selected fluorinated 3-hydroxypyridin-4-ones demonstrate that some such fluorinated compounds have clear advantage over deferiprone in that they are metabolized more slowly. Blood-brain barrier permeability studies indicated that although lipophilicity influences the permeability it is not the only factor. Two of the selected seven fluorinated 3-hydroxypyridin-4-ones have improved brain distribution when compared with deferiprone.